跳到正文
FDA 官方药品与生物制品信息·AI 评分45

FDA合规计划7356.002C《放射性药品》修订版发布(2015-09-11)

Radioactive Drugs (7356.002C)

AI 导读

美国FDA于2015年9月11日发布合规计划7356.002C《放射性药品》修订版,更新了实施日期、完成日期、组织与程序变更及计划联系人。该计划要求各地区局对所有放射性药品检查适用本合规计划,检查报告须通过TurboEIR放射性药品专用模块电子提交;因违反21 CFR Part 210和211 CGMP而被列为OAI的常规商业生产检查,须经MARCS-CMS提交建议措施。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

     FOOD AND DRUG ADMINISTRATION
     COMPLIANCE PROGRAM                                                PROGRAM         7356.002C


                                CHAPTER 56 - DRUG QUALITY ASSURANCE

     SUBJECT:                                                          IMPLEMENTATION DATE

     RADIOACTIVE DRUGS                                                  09/11/2015

     Revision Note: Program revised 09/11/2015 to update
                                                                       COMPLETION DATE
     implementation date, completion date,
     organizational/procedural changes and program
     contacts.

                                          DATA REPORTING
                   PRODUCT CODES                           PRODUCT/ASSIGNMENT CODES

                                              56002C   DPI/RADIOACTIVE DRUGS
     7356.002C




          FIELD REPORTING REQUIREMENTS
         (Excluding Winchester Engineering and Analytical Center [WEAC])

          Establishment Inspection Reports (EIRs) are to be created and filed
          electronically using the radioactive drug specific module in TurboEIR or
          replacement system that is accessible to both ORA and CDER.

          For inspections of routine commercial manufacturing classified as
          Official Action Indicated (OAI) due to failure to comply with 21 CFR
          Part 210 and 211 Current Good Manufacturing Practice (CGMP) as they
          apply to radioactive drugs, submit advisory, administrative, or judicial
          action recommendations via MARCS-CMS in accordance with the Regulatory
          Procedures Manual (RPM).

          Districts should immediately report significant issues according to
          current FACTS, Panorama and CMS procedures. This includes promptly
          filing and changing OAI notifications.

          During an inspection, if you obtain information pertaining to inadequate
          adverse drug experience (ADE) reporting, unapproved drug issues, or
          post-approval reporting violations (application supplements, Field Alert
          Reports (FARs), etc.), report in accordance with directions provided in
          the applicable compliance programs and under separate captions in the
          EIR. Data system information about these inspectional activities should
          be reported under separate Program Assignment Codes (PACs).


Date of Issuance: 09/11//2015                                           COVER   PAGE   1 of 2
)

第 2 页

     FOOD AND DRUG ADMINISTRATION
     COMPLIANCE PROGRAM                                       PROGRAM       7356.002C




         Expansion of coverage under these programs into a CGMP inspection should
         be reported under this compliance program.

         The Districts are requested to use this compliance program for all
         radioactive drug inspections.


         WINCHESTER ENGINEERING AND ANALYTICAL CENTER (WEAC) REPORTING
         REQUIREMENTS

         A.       Forward all worksheets to Home District with copy to CDER/Office
                  of Product Quality (OPQ)/Office of Quality Surveillance(OQS).

         B.       Send by Electronic Mail System (EMS) results of the examination
                  of import samples to Home District.




                                                             COVER   PAGE   2 of 2
Date of Issuance: 09/11//2015

)

第 3 页

  FOOD AND DRUG ADMINISTRATION
  COMPLIANCE PROGRAM                                    PROGRAM    7356.002C


                                PART I - BACKGROUND
History


Radioactive drugs are regulated by the FDA to the same extent that FDA
regulates other drugs. With the exception of certain research uses of
radioactive   drugs   (as    specified   in   21   CFR   361.1),   all
radiopharmaceuticals are considered to be new drugs and subject to the
applicable provisions of the Federal Food, Drug, and Cosmetic Act and
the drug regulations issued under Title 21 of the Code of Federal
Regulations.

Definition
The term "radioactive drug" is defined in 21 CFR 310.3 (n) as any
substance defined as a drug in the FD&C Act which exhibits spontaneous
disintegration of unstable nuclei with the emission of nuclear particles
or photons and includes any nonradioactive reagent kit or nuclide
generator which is intended to be used in the preparation of any such
substance but does not include drugs which contain only trace quantities
of naturally occurring radionuclides. The term "radioactive drug"
includes a "radioactive biological product" as defined in 21 CFR
600.3 (ee).
Exception for Research Use

On July 25, 1975, the FDA established a special provision in 21 CFR
361.1 for certain research uses of radioactive drugs provided:
      •       the research was approved by an FDA Radioactive Drug Research
              Committee;
      •       the amount of active ingredient employed does not cause any
              clinically detectable pharmacological effect in humans;
      •       the amount of radioactive material administered to each
              subject is as low as is practicable; and,
      •       the radiation doses to the critical and target organs are
              within certain specified limits.
Under these condition.~, radioactive drugs are generally recognized as
safe and effective when administered to human research subjects during
the course of a research project intended to obtain basic information
regarding the metabolism (including kinetics, distribution, and
localization) of a radioactively labeled drug or regarding human
physiology, pathophysiology, or biochemistry, but not intended for
immediate therapeutic, diagnostic, or similar purposes or to determine
the safety and effectiveness of the drug in humans for such purposes,
(i.e., to carry out a clinical trial).




Date of Issuance: 09/11//2015                           PART   I   PAGE 1 of 2

第 4 页

    FOOD AND DRUG ADMINISTRATION
    COMPLIANCE PROGRAM                               PROGRAM      7356.002C


Certain basic research studies, e.g., studies to determine whether a drug
localizes in a particular organ or fluid space and to describe the kinetics
of   that  localization, may    have  eventual  therapeutic or    diagnostic
implications, but the initial studies are considered to be basic research
within the meaning of this provision. Compliance Program #7348.809A,
"Radioactive Drug Research Committees", covers the monitoring of radioactive
drugs for these research uses.




Date of Issuance: 09/11//2015                          PART   I   PAGE 2   of 2
)

第 5 页

  FOOD AND DRUG ADMINISTRATION
  COMPLIANCE PROGRAM                                       PROGRAM       7356.002C


                                PART II - IMPLEMENTATION

    OBJECTIVES

    *To provide guidance for conduction inspections of radioactive drug
    manufacturers to determine compliance with the Food, Drug and Cosmetic Act
    and the Current Good Manufacturing Practice Regulations (CGMP), Title
    21, CFR Parts 210 and 211.

   To initiate appropriate action against those manufacturers found to be out
   of compliance.

   To obtain information on key practices, to identify practices which need
   correction or improvement, and to evaluate current good manufacturing
   practices in the radiopharmaceutical industry.*

   Pre-marketing aspects of ' radioactive drug products are covered under
   Compliance Program #7346.832, "Pre-Approval   Inspections."  NDA methods
   validations for radioactive drugs, as for other drugs, will be performed
   by assignment.

    PROGRAM MANAGEMENT INSTRUCTIONS

   This program supplements CP #7356.002, "Drug Process Inspections," *and CP
   7356.002A, "Sterile Drug Process Inspections" by providing specialized
   instructions for conducting inspections of radioactive drug manufacturing
   establishments.

   Assignments for the collection of surveillance samples are issued under CP
   #7356.008, "Drug Product Surveillance."

    Coverage

   The term "radioactive drugs" includes radioactive biological products. A
   radioactive biological product is defined as a biological labeled or
   intended to be labeled with a radionuclide.

         Radioactive  drugs may be administered orally,        by      injection,    or
         inhalation and may be either diagnostic or thereutic.




Date of Issuance: 09/11//2015                              PART   II      PAGE 1 of 3

第 6 页

  FOOD AND DRUG ADMINISTRATION
  COMPLIANCE PROGRAM                                      PROGRAM      7356.002C



            1. A diagnostic radioactive drug functions in vivo as a radioactive
            tracer which is distributed throughout the body, or localized in
            particular organs or structures where the decay of the radioactive
            element is detected externally. It may also be used in in vitro
            clinical studies.

            2. A therapeutic radioactive drug contains ' larger quantities of
            radioactivity for destruction of diseased cells or tissues.

THIS COMPLIANCE PROGRAM DOES NOT COVER RADIOACTIVE MEDICAL DEVICES. A
radioactive medical device is a medical device as defined in Section 201(h)
of the FD&C Act that contains or utilizes radioactive materials.




Date of Issuance: 09/11//2015                              PART   II   PAGE 2 of 3

第 7 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                             PROGRAM     7356.002C


                                 PART III - INSPECTIONAL

    OPERATIONS

    Districts will identify all manufacturers *(Attachment A deleted)* of
    radioactive drugs and radioactive biologics, determine whether they are
    registered under Section 510, and contact Division of Medical Imaging
    Products for verification of the firm's NDA and IND filings.

    An enforcement policy for "nuclear pharmacies" has been stated in 49 FR
    24949 (June 18, 1984).

    A guideline has been issued (May 1984) which aids in distinguishing
    between those operations which are considered the practice of nuclear
    pharmacy, and those operations which constitute the practice of drug
    manufacturing.

    Where an establishment has not registered as a drug manufacturer, but
    manufacturing is suspected, attempt to inspect, and forward the EIR to
    OPQ/ OQS for decision as to follow-up. The EIR should contain full
    documentation explaining why the establishment considers itself a
    pharmacy and why the district believes the establishment to be a drug
    manufacturer.

    Districts will inspect each radioactive drug manufacturer *a minimum of
    once every two years on a surveillance basis* and will schedule
    compliance inspections as needed. *See instructions under CP 7356.002 or
    7356.002A concerning frequency of full vs. abbreviated inspections.* -

    Districts and the Division of Drug Quality Evaluation will issue
    assignments for collecting surveillance samples in coordination with
    Winchester Engineering and Analytical Center (WEAC) under CP #7356.008,
    "Drug Product Surveillance."

    On assignment, the investigator team should review:

         -       All reference materials related to the type of products to be
                 covered by the assignment.

         -       Pertinent manufacturing, analytical, and labeling sections of the
                 IND or NDA, obtained if necessary from the OPQ/OQS.

         -      Compendial requirements for USP/NF products.




Date of Issuance: 09/11//2015                                  PART III   PAGE 1 of 13

第 8 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                          PROGRAM     7356.002C



         -      Current Good Manufacturing Practice Regulations, recognizing the
                differences between standard drug manufacturing procedures and
                the unique custom processing operations employed by the
                radioactive drug and radiobiologic manufacturers.

          -     40 FR 31297 - 31314 (July 25, 1975) (attached)

          -     41 FR 7747 (Feb. 20, 1976) (attached)

          -     41 FR 35171 (Aug. 20, 1976) (attached)

          -     Nuclear Pharmacy Guideline (May 1984)

Investigators selected by the districts to undertake assignments made under
this program will have completed the "FDA Advanced Training Course for Drug
Inspectors, Radiopharmaceuticals."

Districts should consider using an investigator/chemist team in making an
inspection of an establishment which has not been inspected previously. As
complex instrumentation and methodology may be involved, chemists with
education or training in nuclear science either from the district staff,
WEAC, DDC, or DORDP will be made available. The district may wish to use the
expertise of Regional Radiological Health personnel as members of the
investigating team.

Because of the nature of radioactive drugs, most producers manufacture small
batches based on anticipation of market needs, with production schedules
established accordingly. This is particularly true where the radioactive
nuclide has a short half-life and must be prepared, packaged, labeled,
shipped, and used in a relatively short period of time, sometimes in a
matter of hours.

All injectable radioactive drug products must comply with the normal
requirements of safety, sterility, freedom from pyrogens, acceptable pH, and
isotonicity. This is required by the United States Pharmacopeia with some
qualifiers regarding sterility testing. In addition, 21 CFR 211.165(a)
states, "where sterility and/or pyrogen testing are conducted on specific
batches of short-lived radiopharmaceuticals, such batches may be released
prior to completion of sterility or pyrogen testing, provided such testing
is completed as soon as possible."

In cases where it is necessary to permit the radioactivity for short-lived
nuclides to decay to a level allowing safe handling by laboratory personnel
performing the test or so that the radioactivity will not compromise the
test itself (e.g., injure the test animal), a delay in starting the test may
be allowed; however, testing of each batch must be accomplished as soon as
possible. Thus, investigators must realize that the production and quality
control aspects of the formulation of these products achieves an importance
which surpasses that employed in the marketing of the usual medicinal.




Date of Issuance: 09/11//2015                               PART III   PAGE 2 of 13

第 9 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                     PROGRAM     7356.002C


If the district requests additional personnel, they should notify the
Division of Medical Products and Tobacco Program Operations (DMPTPO) with
copy to DORDP (HFD-150), WEAC (HFR-1300) or DPA, as appropriate, at least
three weeks in advance of the scheduled inspection so that a determination
can be made as to the individuals to participate in a given inspection.

Agreement State Programs

The Nuclear Regulatory Commission (NRC) has authority to enter into
agreements with State governments, with the State assuming regulatory
responsibility over the receipt, possession, use, disposal, storage, and
transfer of by-product source and specified quantities of special nuclear
material in that State. The State's program must be compatible with the NRC
program and the State must have the technical capability to protect public
health and safety. In addition to Agreement States, other states may
regulate the use of accelerator-produced or naturally-occurring radioactive
materials which are not controlled by NRC.

Agreement State radiation control personnel are frequently expert in the
detection of the improper use, manufacture, and safe-handling of radioactive
materials. These State Inspectors have the training and calibrated equipment
necessary to conduct radiation monitoring surveys, should it be deemed
necessary, and can readily recognize radiation safety hazards.

The Directory of Personnel Responsible for Radiological Health Programs
lists those professional personnel who administer the State and local
government agencies.

Districts may wish to contact State and local radiation control agencies
through their Regional Radiological Health Representative to obtain their
cooperation. This may include their participation in establishment
inspections as expert advisors on radiation safety, providing no information
normally considered confidential (i.e., IND*/NDA*) is to be covered.

All firms that manufacture and/or produce reactor-produced radiopharma-
ceuticals operate under a license issued by the NRC or a regulatory agency
of an Agreement State. Under the provisions of these licenses, each
manufacturer shall have an individual designated as a Radiation Safety
Officer (RSO) or radiation protection specialist. In addition, those areas
where radioactive drugs are produced and stored shall be posted with a
placard or sign bearing the radiation symbol and describing the radiation
and/or contamination levels, and the precautions to be taken while in those
areas (such as the wearing of protective clothing).




Date of Issuance: 09/11//2015                          PART III   PAGE 3 of 13

第 10 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                       PROGRAM     7356.002C


*Format

Inspections of radiopharmaceutical drug manufacturers will be performed
under two compliance program guides, appropriate to the profile class of the
dosage form being inspected.

Non-sterile dosage form radiopharmaceuticals will be inspected utilizing the
instructions contained in Compliance Program #7356.002, Drug Process
Inspections, supplemented by the instructions peculiar to
radiopharmaceutical drug products contained in this Compliance Program.

Lyophilized and other sterile dosage form radiopharmaceuticals will be
inspected utilizing Compliance Program 7356.002A, *Sterile Drug Process
Inspections*, supplemented by the instructions specific to
radiopharmaceutical drug products contained in this Compliance Program.

Inspections of radiopharmaceutical manufacturing firms will be performed as
either Full Inspections or Abbreviated Inspections. The type of inspectional
option to be selected will be determined following the selection options
described in the Drug Process Compliance Program (7356-002) or *Sterile Drug
Process Inspections* Compliance Program (7356.002A), as relevant to the
product/profile class being covered. NOTE: Whether the Full or Abbreviated
Inspection option is selected, the information requested under this
(7356.002C) Radiopharmaceutical Compliance Program will be collected.*

INVESTIGATIONAL

Determine if establishment is registered under Section 510. Do not advise
that they must register if they consider themselves a pharmacy. See 41 ER
7747 (Feb. 20, 1976).

A.    Radiological Safety

     Investigator teams assigned to inspections of radioactive drug
     manufacturers are expected to be familiar with radiation detection
     equipment and safety precautions as follows:

      Personnel dosimeters - supplied by the ORA Radiological Safety Officer
      on a quarterly basis or as needed. Each badge is personally assigned and
      worn only by the designated investigator or chemist. It is required to
      be worn on the torso at all times during inspections or sampling
      assignments involving procedures of radioactive drugs.

      District Radiological Safety Representatives are responsible for
      ordering and issuing dosimeters, and returning them to the ORA
      Radiological Safety Officer for processing, if necessary. When not in
      use, badges should be stored in a low radiation area away from sources
      of heat and moisture.




Date of Issuance: 09/11//2015                            PART III   PAGE 4 of 13

第 11 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                       PROGRAM      7356.002C


     A self-reading dosimeter with a 0-200 mr range should also be carried
     during these assignments. It should be read before, during, and after the
     plant visit as an indicator of radiation exposure received for the period
     involved. The serial number and initial and final readings of
     self-reading dosimeters should be recorded for future reference.

     Regional and District personnel now have available a personnel monitoring
     device which activates with a noise and light signal when a pre-set dose
     level is reached.

     Handle these instruments with care as they may be discharged by shock if
     dropped.

     Required protective clothing such as smocks, bead and shoe covers, and
     gloves are usually provided by the firm's Radiation Safety Officer (RSO).

     The investigator should exercise particular care in areas where iodine or
     technetium isotopes are being produced or processed to prevent an
     internal dose by inhalation of the iodine or from skin absorption of the
     technetium.

     The firm's health physicist or RSO must accompany the investigator into
     controlled areas where radionuclide-sand radioactive drug products are
     processed, stored, or packaged. Avoid unnecessary handling of objects on
     the premises and follow all safety procedures required by the firm.

     After leaving the firm's controlled area, remove all protective clothing
     by the "inside out" technique. Monitor yourself using the available
     monitoring equipment after washing hands, face, and other exposed areas.
     Leave protective clothing with the firm for disposal or laundering.
                            .1
     Note: Each investigator is personally responsible for taking the
     necessary precautions to reduce exposure to ionizing radiation to the
     lowest possible level.

B. Raw Materials

     Determine the adequacy of each firm's control procedures for handling raw
     materials and components. These would include logging the receipt,
     segregation, sampling, testing, and acceptance/release criteria, and
     storage for:

        1. Product containers and their components (vials, generators,
           closures, syringes, needles, tubing, etc.).

        2. Packaging materials.

        3. Chemicals and other raw materials used in manufacturing, such as
           gelatin, colloidal sulfur, saline solution, buffers, radiochemicals,
           etc.




Date of Issuance: 09/11//2015                             PART III   PAGE 5 of 13

第 12 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                         PROGRAM     7356.002C


     4. Radionuclides.

C. Manufacturing Controls

     Report:

        1. Steps taken by the firm to prevent the absorption of radionuclides
           on the walls of containers and preparation vessels. Document the
           use of any coating materials and the firm's validation that
           absorption does not occur and that delivery of the full dose is
           assured.

        2. Validated procedures utilized by the firm to prevent the carry over
           of by-products from chemical reactions to the finished product.

        3. The adequacy of pH controls during the processing of radioactive
           drugs where pH is critical to the purity or activity of the
           products, (e.g. iodine isotopes).

        4. The accuracy of in-process equipment and the adequacy of controls
           used to check whole bottle activity and/or container volume.

          5. Controls used to maintain the identity of components used in
             assembling kits, generators, etc.

          6. Any failure of the manufacturer to establish acceptable limits on
             theoretical and actual yields for small volume batches or
             radioactive drugs manufactured on special order. Audit
             representative batches manufactured before and during the
             inspections.

          7. Firm's procedures for monitoring the environment, personnel,
             glassware, equipment, and various stages in processing for evidence
             of contamination by radioactive materials.

          8. Methods for retesting stock solutions used in manufacturing. Are
             stock solutions checked for potency, impurities, and sterility
             where required? Is reconciliation performed on the use of stock
             solutions?

     D.    Manufacturing Radioactive Drugs and Radiobiologic Products Which
           Meet Sterility Requirements (refer to CPG 7356.002A, Sterile Drug
           Process Inspections)

     *Report:*

     1. Procedures used to insure that processing equipment, glassware,
        final containers, and other components are free from chemical,
        microbial, pyrogenic, and radioactive contamination.




Date of Issuance: 09/11//2015                              PART III   PAGE 6 of 13

第 13 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                           PROGRAM      7356.002C


       2. If re-use of stock solutions is encountered, the investigator should
          report fully the precautions taken by the firm.

*Some portions deleted from this section due to duplication under the
Sterile Drug Process Compliance Program.

E. Generator Systems

     The use of nuclide generators, such as the Mo 99m/Tt 99m generator, has
     increased in recent years and they pose special problems. When
     encountered during an inspection, report the following information:

     1.     Quality control procedures used in the assembly, testing and re-use
            of the generator-system regarding the following areas:

                -    Assay
                -    Calibration
                -    Sterility
                -    Pyrogens
                -    pH
                -    Contaminants (radioactive and non-radioactive)
                -    Daily elution pattern

     2.     Any use of bacteriostats in the preparation of eluting solutions.

     3.     Instructions provided the user as to the assembly, operation and
            maintenance of sterility.

     4.     Details of any training program designed for hospital personnel
            authorized to use generator systems.

     5.     Determine the manufacturer of the generator and the source of the
            radioactive materials within it.

F. Packaging and Labeling

     1.     Report procedures for storing, issuing and accounting for labeling
            and insert materials. Give particular attention to small custom
            batches.

     2.
            Determine the accuracy of the labeling statement for volume,
            chemical
            content, total activity per unit volume at data and time of
            calibration. Report any difference between actual and theoretical
            activity at date and time of calibration by the firm in comparison
            to the labeled activity.




Date of Issuance: 09/11//2015                                 PART III   PAGE 7 of 13

第 14 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                         PROGRAM     7356.002C



     3.     A determination should be made that the kit label and the label of
            each component of the kit bear the same expiration date which is
            based on the component with the earliest expiration date. The
            procedure used for assuring a single and valid expiration date for
            multi-component kits should be reviewed.

     4.     Examples of labeling are to be submitted to CDER. CDER will review
            storage precautions, directions for use, expiration date, and any
            special limitation statements on product labeling for conformance
            with compendial and/or NDA requirements.

     5.     Determine if in-process content uniformity checks are made on
            capsules and if liquids are examined for fill of container and total
            activity.

     6.     Report firm's procedures for identifying components (kits, syringes,
            dilution bottles, etc.) packaged with the radioactive drug, or
            shipped under separate order.

G. Analytical Controls

     Report:

     1.     Any microbiological, chemical, and pyrogen tests performed on water
            intended for parenteral preparations.

     2.     Tests to establish the potency and purity of reagents and materials
            intended for tagging (e.g., vitamin B 12, colloidal sulfur, gelatin,
            isotonic saline solution, etc.).

     3.     Any analysis of isotopes for radionuclide identification, and
            purity, radiochemical identification, purity, and activity.

     4.     Sterility and/or pyrogen tests performed on presterilized
            components, intermediates, and raw materials used in manufacturing.

     5.     Capsule preparations for content uniformity, chemical content, and
            activity.




Date of Issuance: 09/11//2015                              PART III   PAGE 8 of 13

第 15 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                            PROGRAM     7356.002C


     6. Tests performed on finished radioactive drugs and biologicals as
     follows:

                -    Chemical purity
                -    Radiochemical purity
                -    Radionuclidic identification and/or purity
                -    Total radioactivity (assay or radioassay)
                -    Sterility (USP requires that sterility tests be initiated
                     prior to shipment)
                -    pH and particulate matter
                -    Fill of container and packaging requirements
                -    Pyrogens (where required for injections)
                -    Toxicity
                -    Biodistribution

     Note: Refer to NDA and/or compendial monograph for specific analytical
     requirements.

     7.     Determine if analytical procedures follow NDA commitments and/or
            compendial requirements.

     8.     The date and source of analytical standards.

     9.     Review the frequency and methods for standardizing the house
            standards arid' stock solutions.

     10. Current stability testing programs. Does the program data support
         firm's expiration dating system?

     11. During the first inspection, all instruments used in control
         operations should be listed by name and model number. Any changes in
         instrumentation should be noted on successive inspections.

     12. Method and frequency of calibration of all quality control
         instrumentation.

     13. Determine the actual testing frequency for each test.

H. Complaints

     1.     Check complaint files for drug defects, drug administration
            problems, adverse experience reports, and product rejections.

     2.     Report firm's response to complaints and the dispositions of any
            returned goods.




Date of Issuance: 09/11//2015                                 PART III   PAGE 9 of 13

第 16 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                           PROGRAM     7356.002C


I. Products For Sampling

      Identify products from firm's price list or catalog that should receive
      analytical coverage based on inspectional findings, recalls, complaints,
      etc. This list will be used by the OPQ/OQS in the selection of samples
      for drug surveillance requests under CP #7356.008, "Drug Product
      Surveillance."

      When sampling is necessary to document violations, collect samples of
      products from packaged stock ready for shipment. Select products with
      half-lives sufficiently long so that time necessary for collecting
      shipment and analysis is not a limiting factor.

J. Catalogs and Labeling

      1.     Obtain I copy of the firm's latest catalog or price list. Current
             copies or revisions should be marked for referral to OPQ/OQS.

      2.     Obtain representative labeling of products inspected and attach as
             exhibits.

SAMPLE COLLECTION

Requests to collect radioactive drug surveillance samples, both District-
initiated and Center-initiated will be issued under CP #7356.008, "Drug
Product Surveillance." Compliance samples will be collected at District
discretion or by direction of DDQE. Because the labs must schedule this
workload and remain within NRC radioactive material license possession
limits for the amount of radioactive material which may be on hand at any
time, the Districts will coordinate sampling with WEAC prior to collection.

Where necessary to document Good Manufacturing Practice Regulations (GMP)
deviations and other violations of the Act, official samples should be
collected in the following manner.

     A.     Collection

           1.     Collect documentary samples of raw materials, in-process
                  radioactive drugs, labeling, etc., to document GMP deviations
                  where physical samples are impractical.

           2.     Long-lived radionuclides may be collected from plant stocks or
                  from batches manufactured during the time of inspection and
                  after release by firm's quality control department.




Date of Issuance: 09/11//2015                                PART III   PAGE 10 of 13

第 17 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                          PROGRAM     7356.002C


      3. Many products, especially those of short-lived nuclides, are
         manufactured on order only. In such cases it will be necessary to
         obtain samples from products being packaged (filled) during a plant
         visit. Such sampling must not prevent the manufacturer from meeting
         customer orders. Arrange with the firm to determine the date of its
         next regular production of the required products. If the timing is
         satisfactory to the laboratory, arrange to have an additional amount
         of a batch filled in order to provide for an FDA sample. Arrange with
         the firm for the necessary transportation of the product so that
         the sample will be delivered to the FDA laboratory in sufficient
         time for analysis. The investigator should be present during
         the production in order to observe as closely as possible the
         labeling and filling operation of the product. Select required units
         at random after the product has been filled and labeled.

             Caution: Do not request the firm to manufacture or fill a batch for
             the sole purpose of obtaining a sample.

      4. If during an inspection, GMP deviations which are related to
         potency, sterility, pyrogen problems or other contamination are
         encountered, official samples should be collected. Contact
         OPQ/OQS for assistance, if necessary.

      B. Sample Size:

        1. Collect a minimum of 20 capsules for Sodium iodide 1 131 Capsules,
           Cyanocobalamin Co 57 Capsules, Cyanocobalamin Co 60 Capsules and any
           other product where content uniformity is a compendial or NDA
           requirement.

        2. Collect the smallest commercial unit offered for sale in the median
           dosage range when sampling oral preparations and sterile injections.

        3. If plant conditions indicate the need for sterility, pyrogen, or
           toxicity tests, contact the OPQ/OQS for sampling instructions and
           sample size requirements.

C. Sampling Instructions

        1.    Do not handle the immediate container of any radioactive products.

        2.    Plant personnel should place the immediate container in a suitable
              protective container in accordance with the establishment's
              radioactive materials license and DOT shipping regulations.




Date of Issuance: 09/11//2015                               PART III   PAGE 11 of 13

第 18 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                          PROGRAM      7356.002C


           3. Officially seal the protective container before it is placed in
              the final shipping container. It is not necessary to further
              identify the protective container or to attach a FDA-525 to the
              shipping container.

          4.     Obtain a copy of shipping records and product labeling for
                 attachment to your C/R.

          5.     Request the manufacturer to ship your sample via their normal
                 mode of transportation to the laboratory designated by
                 assignment:

                 U.S. Food & Drug Administration
                 Winchester Engineering and Analytical Center (HFR-NE490)
                 ATTN: Supervisory Chemist
                 109 Holton Street
                 Winchester, Massachusetts 01890

          6.     Report details concerning the product and shipment by telephone
                 to WEAC as follows:

                 a) C/R number and date sampled.
                 b) Name of product, activity, time of filling, expiration date
                      batch code, and number and size of unit(s) collected.
                 c) Name and address of manufacturer.
                 d) Reason for collection and analyses required.
                 e) Carrier and method of transportation, airbill number (when
                       appropriate).
                 f) Shipping date and expected date and time of arrival.
                 g) Pertinent information from shipping records.

          7.     Confirm by EMS the information provided by telephone to the
                 appropriate Radiological Safety Officer or to the RAL Supervisory
                 Chemist, WEAC (HER-NE490) for samples shipped to the Winchester
                 laboratory.

          8.     Prepare a Collection Report as soon as possible and send the
                 Sample Record Copy 4 (salmon) to the analyzing laboratory. Flag
                 the C/R "Radioactive Drug or Radioactive Biological Sample".
                 Forward a copy of the C/R to OPQ/OQS. Attach a copy of shipping
                 records and labeling to your original (white) C/R.

          9.     Under the Remarks section of your C/R report:

                 a) Potency (radioactivity) and the exact time and date the
                    Potency determination was made at the manufacturer or
                    repacker.

                 b) Any unusual or suspected practices which might affect the
                     product.




Date of Issuance: 09/11//2015                                PART III   PAGE 12 of 13

第 19 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                     PROGRAM     7356.002C


IMPORTS

The Administration cannot, at present, readily determine the extent of
importation of radioactive drugs. In order to provide coverage, Districts
will alert Customs and other local officials to advise FDA of all imports
and will maintain surveillance by review of import entry forms, invoices,
etc. When shipments of sufficient size, frequency and suitable half-life are
encountered, consider collection of samples under the District-initiated
portion of the Drug Product Surveillance CP. Consult with the OPQ/OQS and
WEAC before attempting such sampling.

Inspection of foreign manufacturers will be coordinated by the Division of
Medical Products and Tobacco Inspections (DMPTI).

Considerations will be given to the district's ability to sample at port of
entry or at consignee's location (handling and shipping), nature of product,
size of lot, ability of laboratory to analyze, etc.

Release individual shipments being sent to physicians and hospitals after
determining that the drugs meet the requirements of 21 CFR 361.1 or are new
drugs covered by approved NDAs.




Date of Issuance: 09/11//2015                          PART III   PAGE 13 of 13

第 20 页

FOOD AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                        PROGRAM      7356.002C


                                 PART IV - ANALYTICAL

Winchester Engineering and Analytical Center (WEAC) will analyze compliance
radioactive drug samples sent to them under this program. It will assist in
the inspection of these firms and collect samples. WEAC will validate
methodology of NDA's upon request of Division of Imaging Products (DIP).

WEAC will examine samples collected. Official and non-official preparations
will be tested by appropriate methodology which will include, but not be
limited to, the following basic analytical criteria:

    -       Radionuclide identity - demonstrating that the principal
            radionuclide is the one it is declared to be.

    -      Radionuclide purity - identifying and quantifying radionuclide
           contaminants.

    -      Radiochemical identity - demonstrating that the principal chemical
           form of the radionuclide is the one it is declared to be.

    -      Radiochemical purity - showing the fraction of the principal
           radionuclide which is in the specified chemical form.

    -      Radionuclide assay - measuring the radioactivity of the principal
           radionuclide and comparing it 'with the label declaration.

    -      Non-radioactive chemical tests - establishing identity, purity, and
           strength of non-radioactive components.

    -      Sterility or pyrogenicity - determinations, when necessary, will be
           performed by WEAC.

    -      Biological distribution (Biological Efficacy), when necessary, will
           be accomplished through sample preparation and animal work.




Date of Issuance: 09/11//2015                             PART   IV   PAGE 1 of 1

第 21 页

  FOOD AND DRUG ADMINISTRATION
  COMPLIANCE PROGRAM                                                PROGRAM   7356.002C


                         PART V - REGULATORY/ADMINISTRATIVE STRATEGY

In most cases, seizure or recall of small batches of short-lived radioactive
drug products will not be feasible because they are dispensed so quickly.
NAF and regulatory letters, injections and prosecution are other options.
Withdrawal of an NDA or a supplemental NDA is an additional option; however,
it has only been used on very rare occasions.

The Home District will consider all of the inspectional, analytical,
administrative, voluntary and regulatory follow-up options available when a
violative situation is encountered. The district will select the most
appropriate option or combination of options. Appropriate regulatory action
will be recommended to the OPQ/OQS.

*Refer to Part V of the Drug Process Inspections Compliance Program 7356.002
for general information on regulatory procedures.*




Date of Issuance: 09/11//2015                            PART   V         PAGE 1   of 1

第 22 页

    FOOD AND DRUG ADMINISTRATION
    COMPLIANCE PROGRAM                                      PROGRAM       7356.002C


                 PART VI - REFERENCES, ATTACHMENTS AND PROGRAM CONTACTS

REFERENCES

1. Radiation Safety Handbook for Ionizing and Non-Ionizing Radiation, DHEW
   Publication (FDA) 77-8007 *(Current Revision)*

2. Safe Handling of Radioactive Materials, Handbook 92, U.S. Department of
   Commerce, National Bureau of Standards, NCRP Report No. 2 (1964)

3. Remington's Pharmaceutical Sciences, *Current Edition*

4. Briner, W.H., "The Preparation of Radioactive Chemicals for Clinical
   Use,* American J. Hospital Pharm., 20, 553-561 (1963)

5. USP/NF (Current Edition)

6. Radioactive Pharmaceuticals, USAEC. Division of Technical Information
    Extension,  Oak Ridge, TN, April, 1966, AEC Symposium Series No. 6
    CONF-651111. ,

7.    Cliggett, P.A. and Brown, J.M. "Assays of Radioactive Materials for Use
      in Patients - A Five Year Study", Journal of Nuclear Medicine, 9,
      236-240 (1967)

8. Radioisotope Directory, 2nd Edition (1971), Supplement to Dec. 1970
    Nuclear
    News, American Nuclear Society, Hillsdale, IL 60521

9. "Radiation Monitoring", AEC, Division of Technical Information
    Extension, P.O.    Box 62, Oak Ridge, TN 37830

10. AMA Drug Evaluation, Current Edition, American Medical Association,
    Chicago, IL

11. Analytical Control of Radiopharmaceuticals, Proceedings of a Panel,
    Vienna, 7-11 July (1969); International Atomic Energy Agency, Vienna,
    (1970). Panel Proceedings Series. Unipub, Inc., P.O. Box 443, New York,
    NY 10016

12. "Directory of Personnel Responsible for Radiological Health Programs",
    Conference of Radiation Control Program Directors, Inc., 71 Fountain
    Place, Frankfort, KY 40601, published annually.

13. "Radiopharmaceuticals" (1975) Society of Nuclear Medicine, New York




Date of Issuance: 09/11//2015                                PART   VI    PAGE 1 of 3
)

第 23 页

FOOD
  .  AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                            PROGRAM 7 3 5 6 .002C      ATTACHMENT A


         14.     Quality Control in Nuclear Medicine; Buck A. Rhodes (1977)

         15.     Federal Register of June 18, 1984 - 24949-50

        *16. Inspection Technical Guide, "Radiation Protection Terminology,"
              date 5/15/86, Number 44.*

        *17. Regulatory Procedure Manual, Part 8*.

        ATTACHMENTS:

               A.    Radioactive New Drugs and Radioactive Biologics - Termination of
                     Exceptions 40 FR 31297-31313 (July 25, 1975)

                     Radioactive Drugs, Including Biological Products - Notice to
                     Nuclear Pharmacies 40 FR 31314 (July 25, 1975)

               B. Radioactive New Drugs and Radioactive Biologics; Extension of
                   Time for Continued Commercial Distribution
                   40 FR 7747 (Feb.20,1976)

               C. Radioactive New Drugs and Radioactive Biologics; Extension of
                   Time for Continued Commercial Distribution 41 FR 35171 (August
                   20, 1976)

               CONTACTS


               A. ORA
                 Office of Operations (OO)/Office of Medical Products and Tobacco
                 Operations (OMPTO):
                 ORAHQDrugInspectionPOC@fda.hhs.gov


                    ORA/ORO/OR
                    S
                    Telephone: 301-796-6600

               B. CDER

               1. CGMP or any Quality-Related Policy Questions
               For CGMP or any quality-related policy question, technical or
               scientific questions or information needs, including questions about
               this program, please send an email to the following address and it
               will be handled as a top priority:

               CDER-OPQ-Inquiries@fda.hhs.gov




  Date of Issuance: 09/11//2015                                       PART   VI   PAGE 2   of 3

  )

第 24 页

FOOD
  .  AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                          PROGRAM 7 3 5 6 .002C      ATTACHMENT A


               Enforcement-Related Guidance or Policy
               For enforcement-related guidance or policy, including evidence
               need and sufficiency, citations, and case
               evaluation/recommendation advice, please send an email
               to the following address and it will be handled as a top priority:

               CDER OMQ Compliance Policy: CDEROMQCompliance@fda.hhs.gov

               Labeling Requirements and Policies
               Office of Unapproved Drugs and Labeling Compliance, see
               intranet home page for contacts
               [CDER | Office of Compliance | Office of Unapproved Drugs and
               Labeling Compliance]

               Registration and Drug Listing Requirements
               CDER Office of Compliance, see “CDER: Who’s the Lead”
               intranet page for contacts
               [CDER | Office of Communications | CDER: Who’s the Lead]

          2. To report shipments to laboratories and for problems with sample
             collections and analyses, size, etc.:

              a. Winchester Engineering and Analytical Center
                 ORA *(HFR-NE490)*
                 Telephone: FTS 839-8711 (area code 617)

               b. CDER/OPQ/OQS
                  CDERSURVEILLANCE@fda.hhs.gov


          3. For problems concerning radiation safety and protection:

                   Regional Radiological Health Representative,
                   or if not available:

                   Edmond Baratta, Radiation Safety Officer
                   Telephone 781-756-9742
                   Edmond.Baratta@fda.hhs.gov




  Date of Issuance: 09/11//2015                                     PART   VI   PAGE 3   of 3


  )

第 25 页

FOOD
  .  AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                              PROGRAM 7 3 5 6 .002C      ATTACHMENT A


                                  PART VII - CENTER RESPONSIBILITIES



  The OPQ/OQS will review all Establishment Inspection Reports forwarded by the
  Districts. Districts will keep the OPQ/OQS advised of their plans for surveillance
  and compliance sampling. This Division will evaluate
  all laboratory findings.

  CDER will review storage precautions, directions for use, expiration date, and
  any special limitation statements for product labeling for conformance with
  compendial and/or NDA requirements.

  Program
  Evaluation_

  The OPQ/OQS will periodically evaluate this activity. Evaluations will be made
  generally available.




  Date of Issuance: 09/11//2015                                         PART VII   PAGE 1   of 1
  )

第 26 页

FOOD
  .  AND DRUG ADMINISTRATION
COMPLIANCE PROGRAM                                       PROGRAM 7 3 5 6 .002C       ATTACHMENT A


  ED: Attachment A is a copy of the Federal register: not included in scanning.

                                  FRIDAY, JULY 25, 1975
                                  WASHINGTON, D.C.
                                  Volume 40 Number 144
                                  PART II




                                           DEPARTMENT OF
                                              HEALTH,
                                          EDUCATION, AND
                                              WELFARE
                                  Food and Drug Administration


                                         RADIOACTIVE DRUGS
                                          AND RADIOACTIVE
                                        BIOLOGICAL PRODUCTS




  Date of Issuance: 09/11//2015                                                   PAGE 1   of 1

  )

来源:FDA 官方药品与生物制品信息 · fda.gov